Headline: CPT code 89049: Caffeine Halothane Contracture Test for Malignant Hyperthermia Risk

Lead: CPT code 89049 represents the caffeine halothane contracture test (CHCT), a specialized diagnostic laboratory procedure that evaluates a muscle biopsy for susceptibility to malignant hyperthermia (MH). This code covers a high‑impact, low‑volume service essential to perioperative safety and anesthetic planning.

CPT code 89049 denotes a laboratory diagnostic service that determines MH susceptibility by measuring muscle contracture response to caffeine and halothane. Nationally, CHCT is clinically important because it identifies patients at risk for a potentially fatal intraoperative reaction, informing anesthesia choice and perioperative management. The service is typically performed in hospital outpatient laboratories or specialized neuromuscular diagnostic centers and is ordered when clinical history or family history raises concern for MH.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks and context for CPT code 89049, including typical settings of service, clinical indications, and payer coverage considerations. The publication outlines how this code fits into diagnostic pathways for MH, common documentation elements expected for claims, and national policy patterns affecting coverage and utilization.

What readers will learn: an overview of the clinical role of CHCT, where the service is performed, which major payers cover it, and the types of benchmarks and policy updates that influence coding and reimbursement for this specialized diagnostic test.